Deferasirox是什么？

What was launched in China in 2010?

About Deferasirox drug introduction:

Deferasirox is an iron chelator product developed by the Swiss pharmaceutical company Novartis. It is the first oral iron-depleting agent approved by the U.S. FDA for routine use. It is approved for use in patients ≥2 years old with chronic iron overload caused by blood transfusion. In Europe, it is recommended as a first-line drug for patients with thalassemia iron overload over 6 years old;

Domestic clinical research; Phase II and III clinical trials and pharmacokinetic studies have shown that it has good safety and tolerability, can significantly reduce the iron load on the heart and liver, and is easily accepted by patients. At the same time, it also has pharmaceutical properties such as antifungal (such as Mucor that grows in an iron-rich environment), anti-cell proliferation, anti-malarial, anti-oxidative stress damage, anti-cytotoxic-induced apoptosis, etc.; it can be used for the treatment of secondary hemochromatosis, porphyria cutanea tarda and other diseases.

Deferasirox binds to iron stored in the liver, and it also binds to small amounts of zinc and copper, but the significance of these effects is unclear. Almost 3/4 of each dose is absorbed into the bloodstream. Most drugs are broken down in the liver and excreted in the feces. Women excrete this drug 17.5% slower than men, but this does not affect the use and dosage arrangement of the drug.

The advantage of Deferasirox is that it can remove free iron and intracellular iron, prevent myocardial cells from taking up iron, and directly remove excess iron from myocardial cells, resulting in a continuous reduction of non-transferrin in the plasma. It is a first-line drug for patients with chronic iron overload caused by blood transfusion. Deferasirox dispersible tablets can be taken orally once a day, with good patient compliance, ensuring long-term iron removal treatment.

Its excellent iron-removing effectiveness, safety and patient compliance have greatly reduced the mortality of patients with diseases such as thalassemia and MDS that require long-term blood transfusion treatment, and improved their quality of life.